ArticleCardio-oncology (London, England)2026
Temporal trends and forecasted mortality involving lung cancer with co-listed hypertension in U.S. adults, 2000-2035.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung Cancer (LC) and Hypertension (HTN) frequently co-exist as a significant comorbidity with shared risk factors and pathophysiological mechanisms. We examined national trends and forecast future mortality involving LC co-listed with HTN among US adults from 2000 to 2025, with projections to 2035.
methodsUsing CDC WONDER MULTIPLE Cause-of-Death, we conducted a retrospective analysis of LC and co-listed HTN mortality from 2000 to 2025 among adults aged ≥ 25 years. Age-adjusted mortality rates (AAMRs) were calculated, and joinpoint regression was utilized to estimate annual average percentage changes (AAPCs) with 95% confidence intervals (CIs). Auto-ARIMA and Prophet time-series models in R (v4.5.0) projected AAMRs through 2035, evaluated by root mean squared error (RMSE).
resultsThere were 305,878 reported deaths due to LC and co-listed HTN. The AAMR rose from 3.55 to 6.00 (AAPC 2.038; p < 0.0001). Men had higher mean AAMRs than women (mean AAMR: men 6.16; women 4.07). Among races, Non-Hispanic (NH) Black adults had the greatest mortality (mean AAMR: 7.38). Geographically, the South had the greatest burden (mean AAMR: 5.67) and non-metropolitan regions had higher mean AAMR than metropolitan regions (5.73 vs. 4.5). Most deaths (42.16%) occurred in decedents' homes. The overall AAMR was projected to remain persistently elevated through 2035, particularly among men, NH White individuals, and in the Southern region with substantial uncertainty.
conclusionMortality associated with LC and co-listed HTN is an increasing healthcare burden in the US with marked demographic and regional disparities. Future projections indicate a persistent mortality burden, underscoring the need for targeted prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.